Immunos Therapeutics has picked up Pfizer Ventures as an investor as it looks to move its lead immuno-oncology drug candidate into clinical testing.
Immunos Therapeutics, a Switzerland-based immunotherapy spinout of University of Zurich and University of Basel, has completed a CHF15m ($15.3m) series A round co-led by Pfizer Ventures, the corporate venturing arm of pharmaceutical firm Pfizer.
Life sciences-focused venture capital firm BioMedPartners co-led the round, which included VC firm Redalpine, multi-family office Wille Finance, investment firms Schroder Adveq and Bernina BioInvest, and undisclosed private and existing investors.
Founded in 2014, Immunos Therapeutics is working on immunotherapy-driven treatments for cancer and…